Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine plus sertraline versus placebo plus sertraline for obsessive-compulsive disorder
IRCT20170123032145N5Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine and sertraline in obsessive compulsive disorder (OCD) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Severity of obsessive-compulsive disorder. Started Sep 2020; status: completed.
02
Drugs
agomelatinesertraline
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20170123032145N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170123032145N5.